India's first dengue vaccine approved India's drug regulatory authority has approved the Kydenga vaccine against dengue for use. The dengue vaccine has been approved in India. The vaccine named Kydenga, developed by a Japanese company against the dengue virus, has been approved for use in India. Developed by Japanese pharmaceutical company Takeda Pharmaceuticals , this vaccine has been approved by India's drug regulatory authority Central Drug Standards and Organization (CDACO). The Kydenga vaccine is said to provide protection against all four types of dengue virus serotypes 1, 2, 3 and 4 . Like the COVID-19 vaccine , it requires two doses. The second dose should be given three months after the first dose. This vaccine, which can be given to people aged 4 to 60 years, can also be given to those who have not had dengue. This vaccine, which is currently being produced in India, currently costs between Rs 6,000 and Rs 12,000 per dose . The price is expected to come down in ...
Why is the infection of flesh-eating bacteria spreading in Japan? After the control of the Corona epidemic, with the order of mixing with each other returning to the old rhythm in Japan, the Japanese are now fighting a rare disease. There is now an increase in the outbreak of such bacteria, which attack the tissues of the human body. This bacteria is affecting children under 15 years of age more. This bacteria has been named carnivorous, meaning flesh-eating bacteria. This disease caused by hale is called streptococcal toxic shock syndrome (STSS). This bacteria is so dangerous that it kills a person within 48 hours. According to Japan's National Institute of Infectious Diseases, this rare disease has been seen in about 1000 people in Japan so far. This disease has spread not only in Japan but in many other countries. In which there are European countries. Although called flesh-eating bacteria, it does not eat human flesh directly, instead it kills the tissue inside the body. This ...